At insitro, we’re building more than AI-powered drug discovery technologies. We’re working to fundamentally reshape how medicines are discovered through causal human biology, machine learning, and data-driven science. Today, we’re excited to share Deep Phenotype, our new Substack publication dedicated to sharing the ideas, research, and perspectives shaping the future of AI in biology.

Subscribe to Deep Phenotype: https://deepphenotype.substack.com/

Exploring the Intersection of AI and Human Biology

The pace of innovation across artificial intelligence, computational biology, genetics, and drug discovery has never been faster. New foundation models, multimodal datasets, automation technologies, and advances in machine learning are transforming how researchers understand disease biology and identify new therapeutic opportunities.

Whether you’re a scientist, engineer, biotech leader, investor, or simply curious about how AI is reshaping medicine, Deep Phenotype is designed to provide deeper context behind the technologies and scientific advances driving the industry forward.

We’ll explore these developments through the lens of insitro’s scientific and technical leadership, with thoughtful perspectives on topics including:

• Causal human biology and the science behind disease
• The convergence of machine learning, human genetics, and experimental biology
• Building and applying large-scale multimodal human and cellular datasets
• AI-driven target discovery and identifying causal genetic drivers
• Designing better medicines through predictive therapeutic engineering
• The future of drug discovery, translational science, and biomedical AI
• Scientific perspectives from insitro’s researchers, engineers, and drug discovery experts

The conversation is already underway. Our inaugural issue was written by insitro founder and CEO Daphne Koller, a pioneer of AI who has spent nearly three decades advancing machine learning and its application to human biology. In “Drug Discovery Has No Magic Wands,” Daphne argues that to fulfill AI’s promise, we must solve the fundamental bottleneck of disease understanding by identifying the biological mechanisms that actually alter the course of illness, rather than just building “better keys” for the “wrong locks.”

Continuing the Conversation

In the months ahead, Deep Phenotype will share perspectives on the people, platforms, and progress behind insitro. Subscribe to learn how our Virtual Human™ causal AI engine and TherML™ therapeutic design platform are advancing first-in-class programs toward the clinic. Along the way, we’ll share what we’ve learned from collaborations with Bristol Myers Squibb, Lilly, and Gilead — and from a bilingual culture that operates as one discipline.

As AI continues to transform life sciences, we believe thoughtful discussion is just as important as technological innovation. Deep Phenotype creates a space to share ideas, challenge assumptions, and contribute to the conversations shaping the next generation of biomedical discovery.

The future of AI and biology is here. We invite you to subscribe and become part of it. 

Subscribe to Deep Phenotype: https://deepphenotype.substack.com/